1800 103 7100
info@mohanfoundation.org
MOHAN Foundation

Menu

Skip to content
  • About
  • Free Downloads
  • Videos

Alnylam Pharma Reveal Phase IIb Trial With ALN-RSV01 Missed Primary Endpoint

September 4, 2012Transplant Trialsadmin
Alnylam Pharma Reveal Phase IIb Trial With ALN-RSV01 Missed Primary Endpoint

Post navigation

← ALNYLAM PHARMACEUTICALS, INC. : Alnylam Presents Complete Results … – 4-traders Facebook To Spread Organ Donor Initiative to Asia – WebProNews →

Categories

  • Antibodies
  • Blood donation
  • Bone marrow donation and transplantation
  • Brain Death Declaration
  • Chronic Allograft Nephropathy
  • Donor Card
  • Drugs/Medicine
  • Google News RSS feed URL deprecation
  • Heart
  • HLA Typing
  • Immunosuppressive Drugs
  • Infectious Disease
  • Intestinal
  • Islet
  • Kidney
  • Liver
  • Lung
  • Monoclonal Anti-CD20 Antibodies
  • Monoclonal Anti-IL-2Rα Receptor Antibodies
  • Nephrology
  • Organ Donation
  • Organ Donor
  • Organ Failure
  • Organ Preservation Methods
  • Organ Preservation Solution
  • Organs
  • Other Transplantation
  • Pancreas
  • Pharma News
  • Polyclonal Anti-T-Cell Antibodies
  • Tissue Donation
  • Transplant laws
  • Transplant Rejection
  • Transplant Studies
  • Transplant Surgery
  • Transplant Tourism
  • Transplant Trials
  • Transplantation
  • Uncategorized
Copyright © MOHAN Foundation
Powered by WordPress , Theme i-excel by TemplatesNext.
MENU
    • About
    • Free Downloads
    • Videos